Hepatitis B (HBV), Hepatitis C (HCV) and Hepatitis Delta (HDV) Viruses in the Colombian Population-How Is the Epidemiological Situation?
Carregando...
Citações na Scopus
42
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
FERNANDEZ, Maria Fernanda Gutierrez
Citação
PLOS ONE, v.6, n.4, article ID e18888, 6p, 2011
Resumo
Background: Viral hepatitis B, C and delta still remain a serious problem worldwide. In Colombia, data from 1980s described that HBV and HDV infection are important causes of hepatitis, but little is known about HCV infection. The aim of this study was to determine the currently frequency of HBV, HCV and HDV in four different Colombian regions. Methodology/Principal Findings: This study was conducted in 697 habitants from 4 Colombian departments: Amazonas, Choco, Magdalena and San Andres Islands. Epidemiological data were obtained from an interview applied to each individual aiming to evaluate risk factors related to HBV, HCV or HDV infections. All samples were tested for HBsAg, anti-HBc, anti-HBs and anti-HCV markers. Samples that were positive to HBsAg and/or anti-HBc were tested to anti-HDV. Concerning the geographical origin of the samples, the three HBV markers showed a statistically significant difference: HBsAg (p = 0.033) and anti-HBc (p < 0.001) were more frequent in Amazonas and Magdalena departments. Isolated anti-HBs (a marker of previous vaccination) frequencies were: Choco (53.26%), Amazonas (32.88%), Magdalena (17.0%) and San Andres (15.33%) p < 0.001. Prevalence of anti-HBc increased with age; HBsAg varied from 1.97 to 8.39% (p = 0.033). Amazonas department showed the highest frequency for anti-HCV marker (5.68%), while the lowest frequency was found in San Andres Island (0.66%). Anti-HDV was found in 9 (5.20%) out of 173 anti-HBc and/or HBsAg positive samples, 8 of them from the Amazonas region and 1 from them Magdalena department. Conclusions/Significance: In conclusion, HBV, HCV and HDV infections are detected throughout Colombia in frequency levels that would place some areas as hyperendemic for HBV, especially those found in Amazonas and Magdalena departments. Novel strategies to increase HBV immunization in the rural population and to strengthen HCV surveillance are reinforced by these results.
Palavras-chave
Referências
- Mora MVA, 2011, INFECT GENET EVOL, V11, P103, DOI 10.1016/j.meegid.2010.10.003
- Schmunis GA, 2005, CLIN MICROBIOL REV, V18, P12, DOI 10.1128/CMR.18.1.12-29.2005
- Radjef N, 2004, J VIROL, V78, P2537, DOI 10.1128/JVI.78.5.2537-2544.2004
- Gomes-Gouvea MS, 2009, J GEN VIROL, V90, P2638, DOI 10.1099/vir.0.013615-0
- LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259
- Quintero A, 2001, J MED VIROL, V64, P356, DOI 10.1002/jmv.1058
- Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
- HADLER SC, 1984, ANN INTERN MED, V100, P339
- Bostan N, 2010, CRIT REV MICROBIOL, V36, P91, DOI 10.3109/10408410903357455
- Pasquier C, 2005, J MED VIROL, V77, P390, DOI 10.1002/jmv.20468
- WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0
- Le Gal F, 2006, EMERG INFECT DIS, V12, P1447
- BUITRAGO B, 1986, HEPATOLOGY, V6, P1292, DOI 10.1002/hep.1840060611
- Gaeta GB, 2000, HEPATOLOGY, V32, P824, DOI 10.1053/jhep.2000.17711
- MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0
- Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x
- Wu JC, 1998, J GEN VIROL, V79, P1105
- LJUNGGREN KE, 1985, HEPATOLOGY, V5, P299, DOI 10.1002/hep.1840050225
- CASEY JL, 1993, P NATL ACAD SCI USA, V90, P9016, DOI 10.1073/pnas.90.19.9016
- Bensabath G, 1987, Bull Pan Am Health Organ, V21, P16
- BUITRAGO B, 1991, BIOMEDICA, V11, P5
- Carrilho FJ, 1998, THERAPIES FOR VIRAL HEPATITIS, P25
- Shakil AO, 1997, VIROLOGY, V234, P160, DOI 10.1006/viro.1997.8644
- CHAO YC, 1990, VIROLOGY, V178, P384
- de la Hoz F, 1992, BIOMEDICA, V12, P5
- Echevarría José M, 2003, Cad Saude Publica, V19, P1583, DOI 10.1590/S0102-311X2003000600003
- Espinal C, 1998, BIOMEDICA, V18, P216
- FAY OH, 1990, VACCINE, V8, pS100
- GAYOTTO LCD, 1991, PROG CLIN BIOL RES, V364, P123
- Gish RG, 2006, J VIRAL HEPATITIS, V13, P787, DOI 10.1111/j.1365-2893.2006.00787.x
- Beltrân Mauricio, 2005, J Clin Virol, V34 Suppl 2, pS33, DOI 10.1016/S1386-6532(05)80032-0
- MARTINEZ M, 1991, BIOMEDICA, V11, P20
- *MIN SAL, 2002, B EP SEM SIT HEP B C
- *MIN SAL, 1996, MAN NORM TECN ADM PR, pCH11
- Mora MVA, 2010, J GEN VIROL, V91, P501, DOI 10.1099/vir.0.015958-0
- Mora MVA, 2010, J MED VIROL, V82, P1889, DOI 10.1002/jmv.21908
- Prieto F, 2003, BIOMEDICA, V8, P2
- RAMSEY GH, 1931, FEVER JAUNDICE PROVI
- REEVES WC, 1975, AM J TROP MED HYG, V24, P873
- Sakugawa H, 1999, J MED VIROL, V58, P366, DOI 10.1002/(SICI)1096-9071(199908)58:4<366::AID-JMV8>3.0.CO;2-X
- Schmunis GA, 1998, EMERG INFECT DIS, V4, P5
- Slusarczyk J, 2000, VACCINE, V18, pS4, DOI 10.1016/S0264-410X(99)00451-X
- Soza Alejandro, 2010, Ann Hepatol, V9 Suppl, P33
- Tanaka J, 2000, VACCINE, V18, pS17, DOI 10.1016/S0264-410X(99)00455-7
- Te Helen S, 2010, Clin Liver Dis, V14, P1, DOI 10.1016/j.cld.2009.11.009
- Te HS, 2010, CLIN LIVER DIS, V14, pvii, DOI 10.1016/J.CLD.2009.11.009]
- Torres JR, 1996, GUT, V38, pS48, DOI 10.1136/gut.38.Suppl_2.S48
- Watanabe H, 2003, J GEN VIROL, V84, P3275, DOI 10.1099/vir.0.19499-0
- *WHO, 2001, HEP DELT, P18
- Yu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009297